Neuropace Inc
NASDAQ:NPCE
Intrinsic Value
NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. [ Read More ]
The intrinsic value of one NPCE stock under the Base Case scenario is 8.34 USD. Compared to the current market price of 13.56 USD, Neuropace Inc is Overvalued by 39%.
Valuation Backtest
Neuropace Inc
Run backtest to discover the historical profit from buying and selling NPCE stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Neuropace Inc
Current Assets | 92.7m |
Cash & Short-Term Investments | 66.5m |
Receivables | 12.3m |
Other Current Assets | 14m |
Non-Current Assets | 14.9m |
PP&E | 14.4m |
Other Non-Current Assets | 524k |
Current Liabilities | 16.2m |
Accounts Payable | 2.3m |
Accrued Liabilities | 12.8m |
Other Current Liabilities | 1.1m |
Non-Current Liabilities | 70.8m |
Long-Term Debt | 57m |
Other Non-Current Liabilities | 13.8m |
Earnings Waterfall
Neuropace Inc
Revenue
|
65.4m
USD
|
Cost of Revenue
|
-17.3m
USD
|
Gross Profit
|
48.1m
USD
|
Operating Expenses
|
-75.3m
USD
|
Operating Income
|
-27.2m
USD
|
Other Expenses
|
-5.8m
USD
|
Net Income
|
-33m
USD
|
Free Cash Flow Analysis
Neuropace Inc
NPCE Profitability Score
Profitability Due Diligence
Neuropace Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Neuropace Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
NPCE Solvency Score
Solvency Due Diligence
Neuropace Inc's solvency score is 33/100. The higher the solvency score, the more solvent the company is.
Score
Neuropace Inc's solvency score is 33/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NPCE Price Targets Summary
Neuropace Inc
According to Wall Street analysts, the average 1-year price target for NPCE is 18.19 USD with a low forecast of 13.13 USD and a high forecast of 21 USD.
Ownership
NPCE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
NPCE Price
Neuropace Inc
Average Annual Return | -72.22% |
Standard Deviation of Annual Returns | 19.75% |
Max Drawdown | -95% |
Market Capitalization | 377.3m USD |
Shares Outstanding | 28 344 600 |
Percentage of Shares Shorted | 0.65% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company’s novel and differentiated RNS System is the brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. The Company’s RNS System is a platform that delivers care for patients suffering from drug-resistant epilepsy and offers a personalized solution and outcomes to the patients suffering from other brain disorders. RNS System is a device that records brain activity data and clinicians to monitor patients. RNS System monitors the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is engaged in treating other brain disorders including depression, impulse control disorders, memory disorders, and post-traumatic stress.
Contact
IPO
Employees
Officers
The intrinsic value of one NPCE stock under the Base Case scenario is 8.34 USD.
Compared to the current market price of 13.56 USD, Neuropace Inc is Overvalued by 39%.